

For Further Information Contact:

Roy Wolvin
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com

For Immediate Release:

Statin Drugs Gain Traction as Potential Treatment for Alzheimer's Disease

Nymox (NASDAQ:NYMX) Has Global Patent Rights for Statin Drugs for the Treatment and Prevention of Alzheimer's Disease

HASBROUCK HEIGHTS, N.J. (November 10, 2006) Statins, the widely used cholesterol drugs with a global market over \$25 billion, are gaining wide attention as a potential new way of treating Alzheimer's disease (AD) according to recent reports. The *Wall Street Journal* noted the promise of statins for Alzheimer's disease and highlighted the pressing need for new and effective treatments for this major disease (October 17, 2006 *Several Drugs Show Promise For Alzheimer's*). A series of recent scientific studies have explored the link between Alzheimer's disease, cognitive function and high cholesterol levels and other cardiovascular risk factors, and the possible role that statins may have in treating or preventing Alzheimer's disease.

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of AD, including for patients at risk for AD because of vascular-related risk factors or disease.

Statin drugs are widely available cholesterol-lowering drugs with a well-established track record of safety and are the biggest-selling prescription pills in pharmaceutical history with estimated 2004 global sales of \$26 billion.

November is National Alzheimer's Disease Awareness Month and also the 100th anniversary of the first report of Dr. Alois Alzheimer characterizing the hallmarks of the disease. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting an estimated 4.5 million people in the U.S. and 15 million worldwide.

Some of the recent scientific studies and reviews concerning the potential for statin drugs to treat or reduce the risk of AD or loss of cognitive function include *Neurol Res.* 2006; 28:630-6, *Acta Neurol Scand* 2006; 114 (Suppl. 185): 78-86, *Acta Neurol Scand* 2006; 114 (Suppl. 185): 3-7, *J. Neurochem.* 2006; 97:716-723; *Restor. Neurol. Neurosci* 2006; 24:79-95; *Neuromolecular Med.* 2006; 8:319-328, *Neurology* 2005; 65:1388-1394, *J. Neurol. Neurosurg. Psychiatry* 2005; 76:1624-1629, *The American Journal of Medicine* 2005; 118: 48S-53S; *The Lancet Neurology* 2005; 4:841-852; *Current Opinions in Lipidology* 2005; 16: 619-623; *The Lancet Neurology* 2005; 4: 521-2, *Arch Neurol* 2005; 62:1047-51, *Neurology* 2005; 64:1531-8, *Arch Neurol* 2005; 62:753-7, *J Neurol Sci* 2005; 229-230:147-50, and *Arch Gen Psychiatry* 2005; 62:217-24.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later

stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.